Effect of Session Frequency of rESWT on Gastrocnemius Muscle Spasticity in Children With Spastic Type Cerebral Palsy
Launched by RIZKY KUSUMA WARDHANI · Sep 28, 2020
Trial Information
Current as of June 16, 2025
Completed
Keywords
ClinConnect Summary
This study was designed as a double-blinded and randomized controlled trial.
Pediatric CP patients from the Department of Physical Medicine and Rehabilitation at Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo (RSCM) are involved in this research. Participants were selected using the inclusion criteria as follow: 1) children with spastic CP who are 5 - 18 years old, 2) one or two gastrocnemius muscle with an Australian Spasticity Assessment Scale (ASAS) of two or more, 3) at least 6 months since the last botulinum injection on gastrocnemius, 4) no surgical operation on lower limb wi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients with spastic CP aged 5 to 18 years old
- • at least one gastrocnemius with an Australian Spasticity Assessment Scale (ASAS) of 2 or more
- • ability of legal respondent to give written informed consent
- Exclusion Criteria:
- • 6 months or less since the last botulinum injection on hamstring
- • surgical operation on lower limb within the last 12 months
- • severe contracture on gastrocnemius
About Rizky Kusuma Wardhani
Rizky Kusuma Wardhani is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a focus on innovative therapeutic solutions, the organization collaborates with leading healthcare professionals and institutions to conduct rigorous clinical trials that adhere to the highest ethical and regulatory standards. By fostering a culture of transparency and scientific integrity, Rizky Kusuma Wardhani aims to contribute valuable data to the medical community, ultimately enhancing the efficacy and safety of new treatments for a variety of health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jakarta Pusat, Dki Jakarta, Indonesia
Patients applied
Trial Officials
Rizky K Wardhani, M.D., Physiatrist
Principal Investigator
Universitas Indonesia Fakultas Kedokteran
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials